CASI Sells Alesta Stake to BioMarin for $5.9M Net Cash
CASIF has more than doubled off its 52-week low of $0.05.
Summary
CASI Pharmaceuticals sold its Alesta Therapeutics stake to BioMarin for approximately US$5.9 million in net cash, closing August 31, 2026. The proceeds significantly strengthen the company's cash position following a going concern warning in mid-August.
Key Events · M&A and Partnerships · CASIF
-
Alesta Stake Sold to BioMarin
Pursuant to a Share Purchase Agreement, CASI sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc.; the transaction closed on August 31, 2026.
-
$5.9M Net Cash Proceeds
At closing, the company received approximately US$5.9 million in net cash, more than doubling its $3.8 million cash balance reported on August 14, 2026.
-
Contingent Milestone Payments
Subject to the transaction agreement, CASI may receive additional payments upon achievement of specified development and regulatory milestones; such payments are not assured.
-
CID-103 Rights Unchanged
The company's existing licensed rights to CID-103, its lead anti-CD38 monoclonal antibody, remain unchanged as a result of the transaction.
Analysis · CASIF · Life Sciences
The sale of CASI Pharmaceuticals' equity interests in Alesta Therapeutics to BioMarin closed on August 31, 2026, delivering approximately US$5.9 million in net cash proceeds. For a company that reported only $3.8 million in cash and a going concern warning just two weeks ago, this is a critical liquidity event. The proceeds more than double the company's cash position, extending its runway and reducing near-term bankruptcy risk. Additional contingent milestone payments could provide further upside, though they are not assured. The company's core CID-103 rights remain unchanged, so the divestiture does not impair its lead asset.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CASIF was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.05 to $3.09. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.